Carboplatin dosing in the era of IDMS-creatinine; the Cockroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care.

[1]  T. Nolin,et al.  Estimation of Kidney Function in Oncology: Implications for Anticancer Drug Selection and Dosing. , 2019, Clinical journal of the American Society of Nephrology : CJASN.

[2]  S. Tavaré,et al.  New Model for Estimating Glomerular Filtration Rate in Patients With Cancer , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Cathomas,et al.  Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  G. Bertelli,et al.  A comparison of measured and estimated glomerular filtration rate for carboplatin dose calculation in stage I testicular seminoma , 2013, Medical Oncology.

[5]  L. Buie,et al.  Impact of a new assay for measuring serum creatinine levels on carboplatin dosing. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[6]  H. Earl,et al.  Evaluation of glomerular filtration rate estimation by Cockcroft-Gault, Jelliffe, Wright and Modification of Diet in Renal Disease (MDRD) formulae in oncology patients. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[8]  G. Rustin,et al.  Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Pai.  Estimating the glomerular filtration rate in obese adult patients for drug dosing. , 2010, Advances in chronic kidney disease.

[10]  D. Alberts,et al.  Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Rodenhuis,et al.  Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? , 2009, Cancer Chemotherapy and Pharmacology.

[12]  D. Mutch,et al.  Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. , 2008, Gynecologic oncology.

[13]  P. Gibbs,et al.  Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey. , 2008, Journal of oncology practice.

[14]  O. Djurdjev,et al.  Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies. , 2006, Gynecologic oncology.

[15]  W Greg Miller,et al.  Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. , 2006, Clinical chemistry.

[16]  M. Riggs,et al.  Prospective evaluation of carboplatin AUC dosing in patients with a BMI ≥27 or Cachexia , 2006, Cancer Chemotherapy and Pharmacology.

[17]  Alan Gordon,et al.  Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. , 2004, Journal of the National Cancer Institute.

[18]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Rischin,et al.  A comparison of bedside renal function estimates and measured glomerular filtration rate (Tc99mDTPA clearance) in cancer patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  M. Highley,et al.  Estimation of glomerular filtration rate in cancer patients , 2001, British Journal of Cancer.

[21]  M. Extermann,et al.  A practical approach to the older patient with cancer. , 2001, Current problems in cancer.

[22]  L. Rostaing,et al.  Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients. , 1998, Bulletin du cancer.

[23]  E Wiltshaw,et al.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. Yordan,et al.  A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study , 1986, Cancer.

[25]  B. Leyland-Jones,et al.  Results of NCI-sponsored phase I trials with carboplatin. , 1985, Cancer treatment reviews.

[26]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[27]  Roger W. Jelliffe,et al.  Creatinine Clearance: Bedside Estimate , 1973 .

[28]  D. D. Bois,et al.  CLINICAL CALORIMETRY: TENTH PAPER A FORMULA TO ESTIMATE THE APPROXIMATE SURFACE AREA IF HEIGHT AND WEIGHT BE KNOWN , 1916 .